The Hippo

HOME| ADVERTISING | CONTACT US|

» » »

Valcyte for Cytomegalovirus in Children Nashua NH

The U.S. Food and Drug Administration has approved Valcyte (valganciclovir hydrochloride) to prevent cytomegalovirus (CMV) disease in children 4 months to 16 years who are undergoing kidney or heart transplant, Swiss drug maker Roche said Monday.

Rajur Krupa MD
(603) 882-2921
38 Tyler Street
Nashua, NH
 
Dipakkumar M Patel, MD
(603) 880-0921
18 Hollyhock Ave
Nashua, NH
Specialties
Pediatrics
Gender
Male
Education
Medical School: Med Coll, Baroda Univ, Baroda, Gujarat, India
Graduation Year: 1990
Hospital
Hospital: Mount Auburn Hospital, Cambridge, Ma

Data Provided by:
Robey Carol W MD
(603) 880-1440
505 West Hollis Street Suite 101
Nashua, NH
 
Anindita Das, MD
(603) 886-5220
19 Tyler St
Nashua, NH
Specialties
Pediatrics
Gender
Female
Education
Medical School: Calcutta Nat'L Med Coll, Univ Of Calcutta, Calcutta, West Bengal
Graduation Year: 1993

Data Provided by:
New England Urology
(603) 577-3190
280 Main Street
Nashua, NH
 
Dr. Lila Hopson Monahan
(603) 891-0083
383 E Dunstable Rd
Nashua, NH
Specialty
Pediatrics

Pulmonary Associates
(603) 889-4131
168 Kinsley Street Suite 10
Nashua, NH
 
James O'Reilly
(603) 889-6671
155 Kinsley St
Nashua, NH
Specialty
Pediatrics

Data Provided by:
Emory Joseph Kaplan, MD
(603) 595-7388
280 Main St Ste 410
Nashua, NH
Specialties
Pediatrics
Gender
Male
Education
Medical School: Tufts Univ Sch Of Med, Boston Ma 02111
Graduation Year: 1974

Data Provided by:
Gregory Wayne Kaupp, MD
(603) 889-2847
10 Prospect St
Nashua, NH
Specialties
Pediatrics, Internal Medicine-Pediatrics
Gender
Male
Education
Medical School: Univ Of Ma Med Sch, Worcester Ma 01655
Graduation Year: 1998

Data Provided by:
Data Provided by:

Valcyte for Cytomegalovirus in Children

Provided By:

MONDAY, Aug. 31 (HealthDay News) -- The U.S. Food and Drug Administration has approved Valcyte (valganciclovir hydrochloride) to prevent cytomegalovirus (CMV) disease in children 4 months to 16 years who are undergoing kidney or heart transplant, Swiss drug maker Roche said Monday.

CMV disease is a common infection among people who have had an organ transplant. Such patients may be infected with CMV before their surgeries, or be receiving organs that are infected, Roche said in a news release. Children are at increased risk of CMV infection and serious complications when their immune systems are suppressed to prevent rejection of donor organs.

CMV infects about 80 percent of the U.S. population, the company said, and in most cases lies dormant in the body. But when the immune system is weakened, CMV complications could affect the lungs, kidneys, nervous system, liver and gastrointestinal tract -- potentially leading to serious illness or death.

As part of the approval, the FDA sanctioned a new oral liquid form of the drug to allow for easier use in children, Roche said.

The drug has not been evaluated in transplant patients under 4 months of age, the company said.

More information

The FDA has more about this drug's history.

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

®2010 Hippo Press. site by wedu